Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
71
10
16
51
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
4.2%
3 terminated/withdrawn out of 71 trials
94.4%
+7.9% vs industry average
8%
6 trials in Phase 3/4
59%
30 of 51 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (71)
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
Role: collaborator
A Study to Assess the Effects of Probenecid on the Pharmacokinetics of Mirdametinib and Its Metabolites in Healthy Participants
Role: lead
Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants
Role: lead
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Role: lead
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Role: collaborator
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Role: collaborator
Study of Cryoablation and Nirogacestat for Desmoid Tumor
Role: collaborator
Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)
Role: lead
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
Role: lead
A Study of Mirdametinib in People With Central Nervous System Tumors
Role: collaborator
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Role: collaborator
JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study
Role: lead
Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors
Role: lead
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Role: lead
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Role: collaborator
Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma
Role: collaborator
The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)
Role: lead
An Observational Study to Evaluate the Efficacy and Safety of Avelumab + Axitinib Combination in Participants With aRCC (AVION)
Role: lead
Targeting ATR in Soft-tissue Sarcomas
Role: collaborator
Effect of Renal Impairment on Enpatoran Pharmacokinetics
Role: lead